Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 562, Issue -, Pages 23-30Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2019.03.020
Keywords
Oral delivery; Insulin; Cp1-11 peptide; Alginate/chitosan nanoparticles; Bioactivity
Categories
Funding
- National Natural Science Foundation of China [51803173, 21534008]
- Sichuan Province Science and Technology Innovation MiaoZi Funding [2018002]
Ask authors/readers for more resources
To improve the oral efficiency of insulin, a novel oral insulin delivery system was developed, to protect the insulin from destruction, and to deliver monomeric insulin with higher bioactivity. The oral insulin delivery system was developed by using chitosan/alginate nanoparticles as carriers for the oral delivery of Cp1-11 peptide/insulin complex (Cp1-11 peptide/Insulin Loaded Nanoparticle, CILN). There is a supramolecular interaction between the insulin and the Cp1-11 peptide, which could inhibit insulin aggregation and improve its bioactivity. In vitro release studies showed that the pH-responsive CILN system could retain insulin in a simulated gastric buffer solution, and exhibited sustained release of the insulin in simulated intestinal buffer solution. The stability studies indicated that CILN could also protect insulin against degradation by proteases in the gastrointestinal tract. Moreover, the insulin oral delivery system appeared to show excellent hypoglycemic effect, and led to higher pharmacological availability of insulin, compared with free insulin loaded nanoparticles, in diabetic rats. Thus, this study has suggested that insulin complexed with Cp1-11 peptide, followed by encapsulating in chitosan/alginate nanoparticles, providing an effective strategy for an oral insulin delivery system to treat diabetes in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available